KP
KPTI.US Karyopharm Therapeutics Inc
- Market cap
- USD 395K
- P/E
- -
- P/B
- 12.05x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is KPTI.US undervalued?
Graham numberThe Graham number of Karyopharm Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Karyopharm Therapeutics Inc fundamental analysis
No fundamental analysis for Karyopharm Therapeutics Inc yet.
Karyopharm Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and…
Full company profileKaryopharm Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Karyopharm Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 154K | 1.61M | 30.3M | 40.9M | 108M | 210M | 157M | 146M | 145M | 146M | 137M |
| Gross Profit | 154K | 1.61M | -131M | 38.5M | 105M | 206M | 152M | 141M | 139M | 140M | 132M |
| Operating Income | -111M | -131M | -180M | -189M | -172M | -98.3M | -142M | -130M | -119M | -90.7M | -98.6M |
| EBITDA | -110M | -130M | -175M | -183M | -168M | -97.0M | -139M | -118M | -38.6M | -150M | -127M |
| Net Income | -110M | -129M | -178M | -200M | -196M | -124M | -165M | -143M | -76.4M | -196M | -179M |
| EPS | -44 | -42 | -3.14 | -3.22 | -2.72 | -25 | -30 | -19 | -9.41 | -18 | -6.18 |
| Balance Sheet | |||||||||||
| Total Assets | 180M | 180M | 341M | 295M | 313M | 305M | 358M | 240M | 164M | 108M | 111M |
| Total Liabilities | 18.1M | 50.8M | 158M | 245M | 263M | 385M | 375M | 377M | 350M | 401M | 441M |
| Shareholders' Equity | 162M | 129M | 183M | 49.8M | 50.5M | -79.7M | -16.7M | -136M | -186M | -293M | -330M |
| Cash & Short-term Investments | 130M | 146M | 328M | 264M | 273M | 229M | 278M | 191M | 109M | 63.7M | 65.1M |
| Total Debt | - | - | 136M | 112M | 120M | 181M | 179M | 177M | 195M | 234M | 216M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -84.4M | -73.7M | -159M | -191M | -160M | -107M | -150M | -92.7M | -127M | -75.4M | -95.3M |
| Capital Expenditure | 70.0K | 62.0K | 2.36M | 206K | 145K | 5.71M | 118K | 0.00 | 142K | 0.00 | 0.00 |
| Free Cash Flow | -84.5M | -73.8M | -161M | -191M | -160M | -113M | -150M | -92.7M | -128M | -75.4M | -95.3M |
| Ratios | |||||||||||
| ROE | -67.5% | -99.6% | -97.4% | -401.0% | -388.3% | - | - | - | - | - | - |
| ROA | -60.7% | -71.5% | -52.3% | -67.7% | -62.7% | -40.6% | -46.1% | -59.5% | -46.5% | -180.8% | -160.6% |
| Net Profit Margin | -71,153.9% | -8,036.4% | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% | -130.5% |
| Debt to Equity | - | - | 0.74x | 2.24x | 2.37x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Karyopharm Therapeutics Inc dividends
Karyopharm Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Feb 26, 2025.
Who owns Karyopharm Therapeutics Inc
- Insiders 4.65%
- Institutions 95.13%
- Public & others 0.22%
- Shares outstanding 22.7M
- Free float 18.6M
Top funds holding KPTI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 678K | 2.99% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 479K | 2.11% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 297K | 1.31% | 0.00% | Oct 2026 |
| International Biotechnology Ord | 190K | 0.84% | 0.00% | Jul 2026 |
| Fidelity Enhanced Small Cap Core ETF | 188K | 0.83% | +0.27% | Oct 2026 |
| iShares Russell 2000 Value ETF | 153K | 0.68% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 115K | 0.51% | +1.40% | Sep 2026 |
| Abante Quant Value FI | 100K | 0.44% | +44.18% | Aug 2026 |
| iShares Micro-Cap ETF | 60.8K | 0.27% | 0.00% | Oct 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 56.8K | 0.25% | +1.92% | Oct 2026 |
| Bridgeway Ultra-Small Company | 49.9K | 0.22% | 0.00% | Jun 2026 |
| Schwab Small Cap Index | 48.5K | 0.21% | 0.00% | Sep 2026 |
| Fidelity VIP Disciplined Small Cap Init | 47.9K | 0.21% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 39.8K | 0.18% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 37.2K | 0.16% | 0.00% | Sep 2026 |
| Invesco Russell 2000® Dynamic Mltfct ETF | 35.8K | 0.16% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 34.9K | 0.15% | 0.00% | Sep 2026 |
| Nomura Healthcare Fund Class I | 33.3K | 0.15% | 0.00% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 31.5K | 0.14% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 28.3K | 0.12% | -0.38% | Oct 2026 |
Top institutions holding KPTI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 1.92M | 8.45% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.52M | 6.71% | -15.78% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.42M | 6.28% | +50.35% | Jun 2026 |
| BlackRock Inc | 1.42M | 6.26% | +479.34% | Jun 2026 |
| Kalehua Capital Management LLC | 1.37M | 6.05% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 959K | 4.23% | +29.64% | Jun 2026 |
| Catalio Capital Management, LP | 941K | 4.15% | +4.81% | Jun 2026 |
| Avidity Partners Management LP | 924K | 4.08% | -0.32% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 786K | 3.47% | -49.01% | Jun 2026 |
| Two Sigma Investments LLC | 695K | 3.07% | +359.73% | Jun 2026 |
| NEA Management Company, LLC | 577K | 2.54% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 531K | 2.34% | +157.71% | Jun 2026 |
| Ghisallo Capital Management LLC | 500K | 2.20% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 440K | 1.94% | 0.00% | Jun 2026 |
| UBS Group AG | 354K | 1.56% | +82.22% | Jun 2026 |
| State Street Corp | 326K | 1.44% | +303.74% | Jun 2026 |
| Affinity Asset Advisors, LLC | 313K | 1.38% | -37.50% | Jun 2026 |
| Brevan Howard Capital Management LP | 310K | 1.37% | +45.89% | Jun 2026 |
| Millennium Management LLC | 306K | 1.35% | -27.32% | Jun 2026 |
| Boxer Capital Management, LLC | 303K | 1.33% | 0.00% | Jun 2026 |
Karyopharm Therapeutics Inc company profile
- Company name
- Karyopharm Therapeutics Inc
- Ticker
- KPTI.US
- Exchange
- USA Stocks
- Listed since
- Nov 6, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 228
- Fiscal year end
- December
- Address
- 85 Wells Avenue, Newton, MA, United States, 02459-3298
- Phone
- 617 658 0600
- Website
- karyopharm.com
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court f
Karyopharm Therapeutics Inc management
10- Mr. Richard A. Paulson M.B.A.President, CEO & Director · born 1967
- Mr. Stuart PoultonExecutive VP & Chief Development Officer · born 1973
- Dr. Reshma Rangwala M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Research · born 1978
- Dr. Sharon Shacham M.B.A., Ph.D.Co-Founder & Chairman of Scientific Advisory Board · born 1970
- Ms. Kristin AbateVP, Chief Accounting Officer & Assistant Treasurer
- Mr. Michael J. Mano J.D.Executive VP, Chief Legal Officer & Secretary · born 1977
- Mr. James Accumanno J.D.Chief Compliance Officer
- Ms. Lisa DiPaoloExecutive VP & Chief Human Resource Officer
- Mr. Brian Austad Ph.D.Senior Vice President of Pharmaceutical Sciences
- Ms. Sohanya Cheng M.B.A.Executive VP, Chief Commercial Officer & Head of Business Development · born 1983